Read our Recent Headlines

Dave Trading – May 2018

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

April 23 Biotech Update

Sort of a quite start to the week but it is Monday of the first week of earnings, so it is not completely surprising to see a slow start. Obviously.

April 20 Biotech Update

It is all about deal making it appears. We are getting closer to the earnings but deals are happening and might be happening or not happening as the case may.

April 19 Biotech Update

We are starting to enter into earnings season, which will pick up next week. This will obviously be driving price action and there is usually a little more risk/volatility in.

What Do You Need To Know Ahead of Next Week – SRPT CHMP Oral-Explanation

The CHMP meeting will take place next week April 23-26, we have no idea what day exactly is SRPT meeting, (Update 04/23:  today the CHMP published this week agenda and.

April 18 Biotech Update

We certainly seem to be moving away from the macro concerns to more sector specific issues, which is good to finally see. Of course, we are only one news cycle.

April 16 Biotech Update

We had the Syrian strikes over the weekend and for all intents and purposes it was typically political theater, which makes it enough for all sides to declare victory and.



Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!